Vivos Therapeutics, Inc.
VVOS- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001716166
No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Vivos Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −3 vs. Q3 2025
- Shares held
- 658.1K
- −28.6K (−4.2%) vs. Q3 2025
- Total value
- $1.34M
- −$793.2K (−37.3%) vs. Q3 2025
- New holders
- 1
- 6 more added
- Sold out
- 4
- 3 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VVOS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $242.7K |
| Q1 2026 | 25 | $2.15M |
| Q4 2025 | 20 | $1.34M |
| Q3 2025 | 23 | $2.13M |
| Q2 2025 | 19 | $1.27M |
| Q1 2025 | 21 | $1.00M |
| Q4 2024 | 20 | $2.00M |
| Q3 2024 | 23 | $630.7K |
| Q2 2024 | 19 | $433.8K |
| Q1 2024 | 16 | $646.8K |
| Q4 2023 | 18 | $3.12M |
| Q3 2023 | 28 | $860.6K |
| Q2 2023 | 31 | $2.39M |
| Q1 2023 | 30 | $1.71M |
| Q4 2022 | 27 | $629.7K |
| Q3 2022 | 30 | $1.38M |
| Q2 2022 | 28 | $2.82M |
| Q1 2022 | 28 | $6.66M |
| Q4 2021 | 29 | $5.02M |
| Q3 2021 | 37 | $9.14M |
| Q2 2021 | 29 | $11.7M |
| Q1 2021 | 18 | $5.45M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Vivos Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 4 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 7 | $14 | 0.00% | −1,058−99.3% | Reduced |
| Global Retirement Partners, LLC | 23 | $47 | 0.00% | 00.0% | Unchanged |
| Kozak & Associates, Inc. | 49 | $101 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 132 | $267 | 0.00% | +15+12.8% | Added |
| Ronald Blue Trust, Inc. | 160 | $325 | 0.00% | 00.0% | Unchanged |
| Signaturefd, LLC | 547 | $1.11K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1,143 | $2.32K | 0.00% | −5,410−82.6% | Reduced |
| Tower Research Capital LLC (TRC) | 2,965 | $6.02K | 0.00% | +171+6.1% | Added |
| Northern Trust Corp | 12,511 | $25.4K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 12,677 | $25.7K | 0.00% | +12,575+12,328.4% | Added |
| Acorn Wealth Advisors, LLC | 14,776 | $30.0K | 0.01% | +14,776 | New |
| State Street Corp | 24,922 | $50.6K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 27,817 | $56.5K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 40,500 | $82.2K | 0.00% | −500−1.2% | Reduced |
| National Asset Management, Inc. | 43,531 | $88.4K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 56,287 | $114.3K | 0.00% | +2,998+5.6% | Added |
| DRW Securities, LLC | 115,907 | $235.3K | 0.02% | +74,441+179.5% | Added |
| Vanguard Group Inc | 304,161 | $617.4K | 0.00% | +212,700+232.6% | Added |
| Connective Capital Management, LLC | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Strategic Wealth Designers | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −39,279−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |